Focus on Anticoagulation Care

Back to articles

Bleeding risk higher with rivaroxaban compared with dabigatran

KEY POINT

Use of rivaroxaban (Xarelto—Janssen, Bayer) was associated with an increased risk of intracranial hemorrhage and major extracranial bleeding compared with dabigatran (Pradaxa—Boehringer Ingelheim) in patients with nonvalvular atrial fibrillation (AF), according to results of a retrospective analysis of real-world data published online in JAMA Internal Medicine.